Scarica l'app Stockscreener
3.06
1.66%
0.05
Precedente Chiudi:
$3.01
Aprire:
$2.93
Volume 24 ore:
105.49K
Relative Volume:
0.23
Capitalizzazione di mercato:
$73.60M
Reddito:
$66.58M
Utile/perdita netta:
$-19.95M
Rapporto P/E:
-3.3268
EPS:
-0.9198
Flusso di cassa netto:
$-14.27M
1 W Prestazione:
+9.68%
1M Prestazione:
-13.80%
6M Prestazione:
-71.90%
1 anno Prestazione:
-30.93%
Intervallo 1D:
$2.91
$3.085
Intervallo di 1 settimana:
$2.59
$3.12
Portata 52W:
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
Nome
Exagen Inc
Settore
Industria
Telefono
(760) 560-1501
Indirizzo
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
3.06 | 73.60M | 66.58M | -19.95M | -14.27M | -0.9198 |
TMO
Thermo Fisher Scientific Inc
|
491.46 | 182.57B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
191.12 | 135.26B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.55 | 45.24B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.48 | 32.63B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
304.24 | 29.85B | 3.17B | 642.63M | 516.49M | 10.77 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-11 | Iniziato | B. Riley Securities | Buy |
| 2025-07-30 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-07-23 | Iniziato | Craig Hallum | Buy |
| 2022-08-05 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-04-15 | Iniziato | Canaccord Genuity | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Iniziato | Cowen | Outperform |
| 2019-10-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Exagen Inc Borsa (XGN) Ultime notizie
XGN PE Ratio & Valuation, Is XGN Overvalued - Intellectia AI
XGN Technical Analysis & Stock Price Forecast - Intellectia AI
Exagen (XGN) Price Target Increased by 12.20% to 13.41 - MSN
Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
CEO Change: Is Exagen Inc benefiting from innovation trendsMarket Growth Review & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Exagen (XGN) price target decreased by 21.78% to 10.03 - MSN
How Analyst Resets Are Reshaping The Exagen (XGN) Investment Story - Yahoo Finance
Exagen Inc stock gains spotlight ahead of Maryland MedTech Summit 2026 amid diagnostic innovation pu - AD HOC NEWS
Stop Loss: Is Exagen Incs growth already priced inGap Up & High Accuracy Trade Alerts - baoquankhu1.vn
Exagen (XGN) director lists 7,500 restricted stock units in Form 3 - Stock Titan
Exagen Inc. (NASDAQ:XGN) Short Interest Update - Defense World
Exagen (XGN) CFO receives option, RSU grants and ESPP share purchase - Stock Titan
Exagen (XGN) CEO John Aballi awarded new RSUs and options - Stock Titan
Exagen prices public offering of common stock - MSN
Exagen Inc Stock (ISIN: US30063K1051) Faces Headwinds After 2025 Revenue Beat - AD HOC NEWS
Exagen Inc Stock (ISIN: US30063K1051) Faces Headwinds After 2025 Revenue Beat and Cautious 2026 Outl - AD HOC NEWS
Exagen (NASDAQ:XGN) Downgraded by Wall Street Zen to Sell - MarketBeat
Exagen Q4 Earnings Call Highlights - Defense World
Exagen stock price target lowered to $10 by Canaccord on margin outlook - Investing.com UK
KeyBanc cuts Exagen stock price target on pricing headwinds - Investing.com Nigeria
Exagen (XGN): Canaccord Genuity Lowers Price Target to $10.00 | - GuruFocus
Canaccord Genuity Group Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat
Exagen Inc. 2025 Annual Report: Innovative AVISE® Autoimmune Disease Testing, Business Strategy, Pipeline, and Intellectual Property Overview - Minichart
Analyst John Wilkin Lowers Price Target for Exagen (XGN) | XGN S - GuruFocus
KeyBanc cuts Exagen stock price target on pricing headwinds By Investing.com - Investing.com India
Exagen (NASDAQ:XGN) Price Target Cut to $10.00 by Analysts at Craig Hallum - MarketBeat
XGN: Keybanc Lowers Price Target to $10, Maintains Overweight Ra - GuruFocus
KeyCorp Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat
Exagen Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-03-11 - Seeking Alpha
Exagen stock price target lowered to $10 by Canaccord on margin outlook By Investing.com - Investing.com Canada
Exagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadence - MSN
William Blair Maintains Outperform on Exagen Inc. (XGN) March 2026 - Meyka
BTIG cuts Exagen stock price target to $9 on lower revenue outlook By Investing.com - Investing.com India
BTIG cuts Exagen stock price target to $9 on lower revenue outlook - Investing.com India
Exagen (XGN) Rating Maintained by BTIG, Price Target Lowered to $9.00 | XGN Stock News - GuruFocus
Exagen (NASDAQ:XGN) Price Target Lowered to $9.00 at BTIG Research - MarketBeat
Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments By GuruFocus - Investing.com Canada
Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments - GuruFocus
4 Analysts Have This To Say About Exagen - Benzinga
Exagen stock maintains Outperform rating at William Blair By Investing.com - Investing.com India
Exagen stock maintains Outperform rating at William Blair - Investing.com Australia
Exagen Q4 2025 Earnings Call Transcript - MarketBeat
XGN: FY 2025 revenue rose 20% with improved margins and expanded AVISE diagnostics platform - TradingView
Earnings call transcript: Exagen Inc. misses Q4 2025 earnings expectations - Investing.com India
Exagen Inc. Reports Strong Q4 and Full-Year 2025 Financial Results – Earnings Press Release March 2026 - Minichart
Exagen (XGN) Achieves Record Q4 Revenue, Driven by Test Volume G - GuruFocus
XGN Forecasts Significant Revenue Growth by 2026 - GuruFocus
Exagen Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Earnings call transcript: Exagen Inc. misses Q4 2025 earnings expectations By Investing.com - Investing.com South Africa
Exagen Inc Azioni (XGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Exagen Inc Azioni (XGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ABALLI JOHN | President and CEO |
Feb 24 '26 |
Sale |
3.61 |
11,430 |
41,262 |
702,997 |
| Black Jeffrey G. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.61 |
1,584 |
5,718 |
267,442 |
| ABALLI JOHN | President and CEO |
Oct 16 '25 |
Sale |
11.82 |
31,787 |
375,598 |
714,427 |
| Black Jeffrey G. | Chief Financial Officer |
Sep 02 '25 |
Sale |
9.79 |
20,466 |
200,362 |
269,026 |
0.17%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):